Blog
What Is the Best Weight Loss Injection? Every Option, Compared Honestly

QUICK ANSWER
There is no single best weight loss injection for everyone. Three are FDA approved for weight management: Wegovy, Zepbound and Saxenda. Four others people ask about, including Ozempic and Mounjaro, are approved only for type 2 diabetes. B12, lipotropic and HCG injections are not weight loss drugs at all.
KEY TAKEAWAYS
- Ozempic, Mounjaro, Victoza and Trulicity are approved for type 2 diabetes, not for weight management. Their weight management counterparts are Wegovy, Zepbound and Saxenda.
- In the only head to head trial, tirzepatide produced 20.2 percent average weight loss against 13.7 percent for semaglutide over 72 weeks.
- Zepbound is also approved for obstructive sleep apnea in adults with obesity. Wegovy is also approved to reduce cardiovascular event risk and for MASH with advanced fibrosis. Those extra indications often decide the choice.
- HCG injections carry an FDA mandated label stating in capital letters that HCG has not been demonstrated to be effective for obesity.
- B12 injections treat B12 deficiency. The NIH states B12 has no beneficial effect on performance in the absence of a nutritional deficit.
- Weight tends to return after stopping. A 2026 analysis of 9,341 participants found weight returned to baseline on average within about 1.7 years.
Ask what is the best weight loss injection and most pages answer with a ranking. The honest answer is that the question has three parts: which injections are actually approved for weight loss, how they differ, and which one fits your medical history.
This article answers all three. It also covers the injections that are marketed for weight loss but are not weight loss drugs, because that distinction is missing from almost every comparison online.
Table of Contents
Four widely discussed injections are not approved for weight loss
This is the most common source of confusion, and it matters because the approved indication determines what a provider can prescribe and what insurance will consider.
Semaglutide and tirzepatide each exist under two different brand names with two different approvals. Same molecule, different product, different indication.
| Brand | Molecule | FDA approved for | Frequency |
| Wegovy | Semaglutide | Weight management. Also reducing major cardiovascular event risk in adults with established cardiovascular disease plus obesity or overweight, and MASH with moderate to advanced fibrosis | Once weekly injection |
| Ozempic | Semaglutide | Type 2 diabetes only. Glycemic control, cardiovascular risk reduction in type 2 diabetes with cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease. Not indicated for weight loss | Once weekly injection |
| Zepbound | Tirzepatide | Weight management. Also moderate to severe obstructive sleep apnea in adults with obesity | Once weekly injection |
| Mounjaro | Tirzepatide | Type 2 diabetes only. Not indicated for weight loss | Once weekly injection |
| Saxenda | Liraglutide 3.0 mg | Weight management in adults, and in patients 12 and over weighing more than 60 kg | Once daily injection |
| Victoza | Liraglutide | Type 2 diabetes only. Not indicated for weight loss | Once daily injection |
| Trulicity | Dulaglutide | Type 2 diabetes only. Not indicated for weight loss | Once weekly injection |
People do lose weight on Ozempic and Mounjaro. That is a known effect of the molecule, not the approved use of that product. When a prescription is written for weight management, the weight management product is the one that matches the indication.
The FDA approved weight loss injections, compared
| Injection | Average weight change in its main trial | Trial detail | Notes |
| Zepbound (tirzepatide) | Minus 16.0 percent at 5 mg, minus 21.4 percent at 10 mg, minus 22.5 percent at 15 mg, against minus 2.4 percent on placebo | SURMOUNT-1, 72 weeks, 2,539 participants, New England Journal of Medicine 2022 | Acts on two receptors, GLP-1 and GIP |
| Wegovy (semaglutide) | Minus 14.9 percent against minus 2.4 percent on placebo | STEP 1, 68 weeks, 1,961 participants, 73 percent female, New England Journal of Medicine 2021 | Acts on the GLP-1 receptor |
| Saxenda (liraglutide) | Minus 8.0 percent against minus 2.6 percent on placebo | SCALE, 56 weeks, 3,731 participants, New England Journal of Medicine 2015 | Daily rather than weekly injection |
Trial averages are not predictions. They describe what happened to a group of people under trial conditions, alongside diet and activity support. Our GLP-1 weight loss projection calculator will show you what a given percentage looks like against your own starting weight, which is usually more useful than a percentage in the abstract.
What the head to head trial found
Until recently these medications had only been compared indirectly. SURMOUNT-5 changed that.
The trial randomised 751 adults and ran for 72 weeks. Tirzepatide produced an average 20.2 percent reduction in body weight. Semaglutide produced 13.7 percent. Waist circumference fell 18.4 cm against 13.0 cm. It was published in the New England Journal of Medicine in 2025.
One finding is often left out. Discontinuation for gastrointestinal side effects was lower on tirzepatide at 2.7 percent than on semaglutide at 5.6 percent. The more effective drug was also the better tolerated one in that trial.
That does not settle the choice. We go through how a provider weighs the two in our guide to semaglutide compared with tirzepatide.
The injections that are not weight loss drugs
Search results for the best weight loss injection routinely include three things that are not weight loss medication. Each is worth understanding on its own terms.
HCG injections
The FDA approved label for chorionic gonadotropin carries a statement in capital letters. It reads that HCG “has not been demonstrated to be effective adjunctive therapy in the treatment of obesity,” and that there is “no substantial evidence that it increases weight loss beyond that resulting from caloric restriction.”
The same label adds that HCG “has no known effect on fat mobilization, appetite or sense of hunger, or body fat distribution.” This is not an outside critique. It is the required text on the product’s own label.
Vitamin B12 injections
B12 injections treat B12 deficiency, and for people with pernicious anemia or a malabsorption problem they are genuinely important. The NIH Office of Dietary Supplements states that B12 “appears to have no beneficial effect on performance in the absence of a nutritional deficit.”
B12 is not a weight loss drug. It can matter alongside one, because eating substantially less changes nutrient intake. We cover that separately in our article on B12 and semaglutide.
Lipotropic or MIC injections
MIC stands for methionine, inositol and choline, usually combined with B vitamins. These are compounded preparations. They are not FDA approved drug products, and no FDA approval exists for them as a weight loss treatment.
Being direct about the evidence: we could not identify a position from the FDA, the NIH, Cochrane or a major obesity society evaluating MIC injections for weight loss. The published evidence base is thin. Anyone presenting them as equivalent to a GLP-1 medication is going beyond what the evidence supports. You can read what the AHC Megaburn MIC and B12 injection is and is not on its own page.
NAD+, sermorelin and glutathione are sometimes grouped into these lists too. They are longevity and wellness injections with different purposes, covered in our guide to longevity injections.
How the side effects compare
Gastrointestinal effects are the most common reason people stop. These figures come directly from the FDA labels and are compared against placebo in the same trial.
| Side effect | Wegovy 2.4 mg vs placebo | Zepbound 15 mg vs placebo |
| Nausea | 44 percent vs 16 percent | 28 percent vs 8 percent |
| Diarrhea | 30 percent vs 16 percent | 23 percent vs 8 percent |
| Vomiting | 24 percent vs 6 percent | 13 percent vs 2 percent |
| Constipation | 24 percent vs 11 percent | 11 percent vs 5 percent |
The FDA label notes these reactions were most frequently reported during dose escalation. Most are described as mild to moderate and they generally settle.
Who should not take a GLP-1 injection
Both Wegovy and Zepbound carry a boxed warning, the FDA’s most serious warning category.
The Wegovy warning states that in rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether the same happens in humans. Zepbound carries an equivalent warning based on rat data.
Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma, and in people with Multiple Endocrine Neoplasia syndrome type 2.
- They are not appropriate during pregnancy, and weight loss offers no benefit to a pregnant patient.
- They require care in people with a history of pancreatitis or gallbladder disease.
- Risk of low blood sugar increases when combined with insulin or a sulfonylurea.
- Serious hypersensitivity to the medication rules it out.
This is not the full list. It is the reason a licensed provider reviews your history before anything is prescribed.
What happens when you stop
This is the question that should shape the decision more than the efficacy ranking, and it is the one most comparisons skip.
In the STEP 1 trial extension, participants who stopped semaglutide regained 11.6 percentage points of body weight over the following 52 weeks, which is roughly two thirds of what they had lost.
A 2026 analysis in the BMJ pooled 37 studies covering 9,341 participants. Weight returned to baseline on average about 1.7 years after stopping. For semaglutide and tirzepatide specifically, first year regain averaged 9.9 kg.
Obesity medicine treats this as expected rather than as failure. These medications manage a chronic condition, and stopping them tends to reverse the effect. We cover what a restart looks like in restarting a GLP-1 after a break.
How to choose the right weight loss injection
Rather than a ranking, here is the reasoning a provider actually works through.
| If this describes you | What it points toward |
| You have type 2 diabetes as well as obesity | A product approved for both, discussed with the prescriber managing your diabetes |
| You have established cardiovascular disease | Wegovy carries a specific cardiovascular risk reduction indication |
| You have moderate to severe obstructive sleep apnea | Zepbound carries a specific indication for this |
| You have MASH with advanced fibrosis | Wegovy carries a specific indication for this |
| You have had significant nausea on a GLP-1 before | Worth discussing, given the lower gastrointestinal discontinuation rate seen with tirzepatide in SURMOUNT-5 |
| A weekly injection is manageable but a daily one is not | Rules out Saxenda, which is daily |
| You have a personal or family history of medullary thyroid carcinoma or MEN 2 | These medications are contraindicated. Do not proceed |
| You are pregnant, breastfeeding or trying to conceive | Not appropriate. Speak to your provider about timing |
Cost is part of the decision too. Prices vary widely by product, pharmacy and insurance status, and many plans do not cover weight management medication at all. Our GLP-1 cost and savings calculator lets you model what a course would actually cost you.
What about compounded versions
Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies. They are not FDA approved products. The FDA does not review them for safety or effectiveness before they are dispensed, and that is an important difference from the branded products described above.
One documented risk is worth knowing. In July 2024 the FDA alerted providers and patients to dosing errors with compounded semaglutide. Patients confused units with milligrams and drew 50 units instead of 5. Reported overdoses ran from 5 to 20 times the intended dose, with effects including vomiting, dehydration, acute pancreatitis and gallstones. Some people were hospitalised.
If you are prescribed a compounded product, make sure you understand the dose in the units marked on your syringe. Our GLP-1 units to mg converter exists for exactly this reason.
| Provider and compliance review required The regulatory position on compounded GLP-1 medication has changed repeatedly since 2024 and continues to develop. This section should be checked against the current FDA position immediately before publishing and re-checked periodically after. |
Frequently asked questions
What is the best weight loss injection overall?
By average weight reduction in trials, tirzepatide has produced the largest figures, including 22.5 percent at the 15 mg dose in SURMOUNT-1 and 20.2 percent against semaglutide’s 13.7 percent in the head to head SURMOUNT-5 trial. Best for an individual depends on medical history, other conditions, tolerance and cost.
Is Ozempic a weight loss injection?
Ozempic is FDA approved for type 2 diabetes, not for weight management. It contains semaglutide, the same molecule as Wegovy, which is the semaglutide product approved for weight management.
Is Mounjaro approved for weight loss?
No. Mounjaro is approved for type 2 diabetes. Zepbound is the tirzepatide product approved for weight management.
Which weight loss injection has the fewest side effects?
No trial ranks them for tolerability across the board. In SURMOUNT-5, the only head to head comparison, discontinuation for gastrointestinal side effects was 2.7 percent on tirzepatide against 5.6 percent on semaglutide.
Do B12 injections help you lose weight?
Not on their own. B12 injections treat B12 deficiency. The NIH states B12 appears to have no beneficial effect in the absence of a nutritional deficit.
Are lipotropic or MIC injections effective for weight loss?
They are not FDA approved for weight loss and the published evidence base is limited. No major regulatory or scientific body has issued a position supporting them as a weight loss treatment.
Does the HCG diet work?
The FDA approved label for chorionic gonadotropin states that HCG has not been demonstrated to be effective in the treatment of obesity and has no known effect on appetite or fat distribution. Any weight lost on an HCG protocol is attributed to the severe calorie restriction that accompanies it.
How quickly do weight loss injections work?
The trial figures above were measured over 56 to 72 weeks. Doses are increased gradually over the first months, so early weeks are about tolerance rather than results. Individual response varies and no timeline can be promised.
Will I regain the weight if I stop?
Most people regain a substantial amount. The STEP 1 extension found about two thirds of lost weight returned within a year of stopping, and a 2026 BMJ analysis of 9,341 participants found weight returned to baseline on average within roughly 1.7 years.
Can I switch from one weight loss injection to another?
Switching is common and is a clinical decision. Dosing does not transfer directly between molecules, so a switch is planned and supervised rather than swapped.
Are there weight loss injections that are not GLP-1 medications?
Among FDA approved options for weight management, no. Wegovy, Zepbound and Saxenda all act on the GLP-1 receptor, with Zepbound also acting on GIP. B12, lipotropic and HCG injections are not approved weight loss drugs.
What new weight loss injections are coming?
Several are in development, including retatrutide and CagriSema. Neither is FDA approved and neither is available by prescription. Reported trial figures are from company releases and should be read as preliminary.
Where to go from here
The best weight loss injection is the one that matches your medical history, your other conditions and what you can sustain. That is a conversation, not a ranking. Before you have it, our BMI calculator and the wider set of weight loss calculators will give you the numbers a provider will ask about.
You can start a free evaluation with Alternate Health Club. A licensed US provider reviews your information individually and will tell you if treatment is not appropriate for you.
Medical Disclaimer
This article is for general educational purposes and is not medical advice. It does not replace a consultation with a licensed healthcare professional. Compounded medications are not FDA approved. Brand names are used for educational identification only and do not imply any affiliation or endorsement. Do not start, stop or change any medication without speaking to a qualified provider. Individual results vary and no outcome is guaranteed.